Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezabenlimab (BI 754091) and mDCF (Docetaxel, Cisplatin and 5-fluorouracil) Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. A Phase II Study

Next Previous
X
Search
Trial Profile

Ezabenlimab (BI 754091) and mDCF (Docetaxel, Cisplatin and 5-fluorouracil) Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. A Phase II Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Ezabenlimab (Primary) ; Fluorouracil (Primary) ; Capecitabine; Mitomycin
  • Indications Anal cancer; Carcinoma; Squamous cell cancer
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms INTERACT-ION

    • Most Recent Events

    • 20 Jan 2024 Preliminary results ( At analysis cut-off date,n=43 )presented at the 2024 Gastrointestinal Cancers Symposium
    • 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.
    • 25 May 2023 Planned End Date changed from 5 Jul 2025 to 5 Jul 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top